![]()  | |
| Clinical data | |
|---|---|
| Other names | 5-OCF3-DMT | 
| Identifiers | |
  | |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C13H15F3N2O | 
| Molar mass | 272.271 g·mol−1 | 
| 3D model (JSmol) | |
  | |
  | |
5-TFMO-DMT (5-(trifluoromethoxy)-DMT, 5-OCF3-DMT, 5-(trifluoromethoxy)-N,N-dimethyltryptamine) is a psychedelic tryptamine derivative related to drugs such as 5-MeO-DMT and DMT (DMT). It acts as an agonist at the 5-HT2A receptor with an EC50 of 127.2 nM.[1] It was shown to release serotonin (5-HT) from synaptosomal preparations, and to reduce immobility time in the forced-swim test in animal studies, suggesting that it might have antidepressant activity.[1]
See also
References
- 1 2 WO 2022/235927, Kruegel AC, "NOVEL TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS.", published 10 November 2022, assigned to Gilgamesh Pharmaceuticals, Inc..
 
  | 
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.
